A recent publication using Prospection’s real-world data analytics shows, 1 in 5 Australian patients with schizophrenia [1] is medicated with older typical long acting injectable (LAI) antipsychotics. Schizophrenia is one of the to...
To examine whether high coronary risk patients in Australia, where
use of lipid-lowering drugs (LLD) is very high by international standards, are
receiving LLD.
Aim: To describe the persistence of biologic disease modifying anti-rheumatic drugs (bDMARDs) in Australian
rheumatoid arthritis (RA) patients, and assess the influence of methotrexate and other conventional DMARD
(cDMARD) concomitant me...
Schizophrenia is a mental health disorder characterised by hallucinations, delusions and disorganised behaviour. The Australian pharmaceutical benefits scheme (PBS) reimburse a number of antipsychotic therapies, however, there is little...
Introduction: To describe the persistence of treatment with subcutaneous tumor necrosis factor inhibitors (TNFi) adalimumab, etanercept, and golimumab in immune-mediated rheumatic dis-
ease (rheumatoid arthritis, psoriatic arthritis, and...
